Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

NCT02704858 is registered in ClinicalTrials.gov with Neonc Technologies, Inc. as lead sponsor.

NCT NCT02704858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02704858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
Lead sponsor
Neonc Technologies, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 1, 2017
Completion date
December 31, 2026
Enrollment
49 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme